What this Trial Is About

Researchers are studying ovarian cancer patients with defective DNA repair systems to understand how PARP inhibitor (PARPi) maintenance therapy affects treatment outcomes and quality of life. This study focuses on two PARPis, niraparib and olaparib, which work by targeting DNA repair defects, especially in patients with homologous recombination deficiency (HRD). The study aims to provide personalized information about the benefits and side effects of PARPi therapy, particularly for patients in Saskatchewan who respond to platinum-based chemotherapy. It also evaluates cost-effectiveness and quality of life impacts of niraparib, which has a different side effect profile compared to olaparib. Participants who are homologous recombinant proficient (HRP) will receive a patient decision aid developed specifically for HRD-tested ovarian cancer patients. This tool supports women in deciding whether to use PARPi therapy by weighing the potential delay in cancer progression against the decrease in quality of life during the first 6 to 12 weeks of treatment. The study is funded by Ovarian Cancer Canada and is conducted in a real-world setting to better inform future treatment decisions. Participants will provide oral consent and complete questionnaires in English as part of the study activities. The main outcome measured is the patient's decision regarding the use of PARPi therapy after six months. The study monitors treatment outcomes, quality of life, and cost-effectiveness to help understand the value of PARPi therapy in this patient group. Total study duration and additional follow-up details are not specified.

Patient Preferences for Precision Medicine: Determining Optimal Patient Quality of Life Using PARPi's